RMD Open 2017;3:e000416. DOI:10.1136/rmdopen-2016-000416Evidence is presented that treatment with sarilumab demonstrates patient-reported benefits in TNF-IR patients with moderate to severe RA. These improvements complement the clinical efficacy previously reported for sarilumab, and are consistent with those seen in the MOBILITY trial (MTX-IR patients)1, yet in a more difficult-to-treat population.Data were analysed from the 24-week Phase 3 TARGET randomised controlled trial in adult patients with active RA and previous inadequate response or intolerance to ≥1 TNF inhibitor. Patients received subcutaneous placebo or sarilumab 150 mg or 200 mg every 2 weeks in combination with csDMARDs, for 24 weeks.PROs assessed were: Patient Global Assessment of Arthritis (PtGA), Pain, HAQ-DI, the Short-Form [SF]-36 domains (physical functioning, role physical, bodily pain, general health perceptions, vitality, social functioning, role emotional, and mental health), fatigue, household work productivity and participation in family/social activities, morning stiffness, and the effect of RA on patients’ lives.Both doses of sarilumab in combination with csDMARDs resulted in clinically meaningful patient-reported benefits at 12 and 24 weeks with respect to pain, fatigue, function, participation and health status, which exceeded placebo plus csDMARDs.1. Strand V, et al. Arthritis Res Ther 2016;18:198.